SG11201909457XA - Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 - Google Patents
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1Info
- Publication number
- SG11201909457XA SG11201909457XA SG11201909457XA SG11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA
- Authority
- SG
- Singapore
- Prior art keywords
- tarrytown
- new york
- international
- rule
- saw mill
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 title abstract 3
- 208000019693 Lung disease Diseases 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102100033500 Interleukin-33 Human genes 0.000 abstract 3
- 108010067003 Interleukin-33 Proteins 0.000 abstract 3
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 abstract 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 2
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo ommolionoimoilowo Hs (10) International Publication Number WO 2018/190990 Al (51) International Patent Classification: C12Q 1/6883 (2018.01) (21) International Application Number: PCT/US2018/023266 (22) International Filing Date: 20 March 2018 (20.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,077 13 April 2017 (13.04.2017) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: BRUSE, Shannon; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). MCCARTHY, Shane; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). BARAS, Aris; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). DEWEY, Fred- erick; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). GOTTESMAN, Omri; 777 Old Saw Mill Riv- er Road, Tarrytown, New York 10591 (US). = (74) Agent: LEGAARD, Paul K.; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, Penn- sylvania 19355-1481 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 1-1 O O 1-1 00 1-1 O C (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS HAVING RISK ALLELES IN THE GENES ENCODING IL33 AND IL1RL1 (57) : IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909457XA true SG11201909457XA (en) | 2019-11-28 |
Family
ID=61911717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909457X SG11201909457XA (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (en) |
| EP (2) | EP3610041A1 (en) |
| JP (2) | JP7321939B2 (en) |
| KR (2) | KR20230164197A (en) |
| CN (1) | CN110431240A (en) |
| AU (1) | AU2018252974B2 (en) |
| CA (1) | CA3059350A1 (en) |
| IL (2) | IL269873B1 (en) |
| MX (2) | MX2019012171A (en) |
| SG (1) | SG11201909457XA (en) |
| WO (1) | WO2018190990A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7165618B2 (en) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | How to determine the risk of allergic rhinitis |
| MX2024005769A (en) * | 2021-11-11 | 2024-05-24 | Regeneron Pharma | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33). |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| DE16192152T1 (en) | 2000-05-26 | 2020-08-06 | Immunex Corporation | USE OF INTERLEUKIN-4 RECEPTOR (IL-4R) ANTIBODIES AND COMPOSITIONS THEREOF |
| GEP20104991B (en) | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (en) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | Methods and compositions for treating asthma in human and non human primates |
| CN1896275B (en) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | PCR kit for detecting SNP (single nucleotide polymorphism) related to chronic obstructive pulmonary disease |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| DK2769992T3 (en) | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Human antibodies with high affinity for human IL-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2010067381A1 (en) | 2008-12-12 | 2010-06-17 | Decode Genetics Ehf | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| ES2655079T3 (en) | 2009-09-10 | 2018-02-16 | Merck Sharp & Dohme Corp. | Use of IL-33 antagonists to treat fibrotic diseases |
| CA2824500C (en) | 2011-02-23 | 2020-02-25 | Georg Fertig | Antibodies against human il33r and uses thereof |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (en) | 2012-05-18 | 2014-12-30 | Amgen Inc | PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER |
| CN110624107A (en) | 2012-08-21 | 2019-12-31 | 赛诺菲生物技术公司 | Methods of treating or preventing asthma by administering IL-4R antagonists |
| WO2014090800A1 (en) * | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
| JO3532B1 (en) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
| CA2904377C (en) * | 2013-03-15 | 2021-07-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| TWI682781B (en) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| FI3088517T3 (en) | 2013-12-26 | 2023-11-30 | Mitsubishi Tanabe Pharma Corp | Human anti-il-33 neutralizing monoclonal antibody |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| NO2785538T3 (en) | 2014-05-07 | 2018-08-04 | ||
| EA201791029A1 (en) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION |
| JP7231326B2 (en) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| MX2017006286A (en) * | 2014-11-14 | 2018-01-23 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist. |
| CN104531689A (en) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | Gene single nucleotide polymorphic sites related to asthma, kit for treating asthma and application of kit |
| WO2016156440A1 (en) | 2015-03-31 | 2016-10-06 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| AU2016333903B2 (en) * | 2015-10-06 | 2021-07-08 | Regeneron Pharmaceuticals, Inc. | Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof |
| TWI784988B (en) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | Methods of treating inflammatory conditions |
-
2018
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 IL IL269873A patent/IL269873B1/en unknown
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/en unknown
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/en active Active
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
- 2018-03-20 EP EP21162316.0A patent/EP3957752A3/en active Pending
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 IL IL314591A patent/IL314591A/en unknown
- 2018-03-20 CN CN201880018649.2A patent/CN110431240A/en active Pending
- 2018-03-20 KR KR1020237039438A patent/KR20230164197A/en not_active Application Discontinuation
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en unknown
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/en active IP Right Grant
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/en unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US20230374145A1/en active Pending
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL314591A (en) | 2024-09-01 |
| AU2018252974B2 (en) | 2024-10-17 |
| CN110431240A (en) | 2019-11-08 |
| EP3610041A1 (en) | 2020-02-19 |
| US11708415B2 (en) | 2023-07-25 |
| RU2019136253A (en) | 2021-05-13 |
| KR20190140928A (en) | 2019-12-20 |
| IL269873B1 (en) | 2024-09-01 |
| US20200031922A1 (en) | 2020-01-30 |
| RU2019136253A3 (en) | 2021-12-17 |
| CA3059350A1 (en) | 2018-10-18 |
| KR20230164197A (en) | 2023-12-01 |
| JP2023129607A (en) | 2023-09-14 |
| MX2019012171A (en) | 2019-11-25 |
| WO2018190990A1 (en) | 2018-10-18 |
| JP7321939B2 (en) | 2023-08-07 |
| JP2020516289A (en) | 2020-06-11 |
| MX2024002689A (en) | 2024-03-20 |
| IL269873A (en) | 2019-11-28 |
| EP3957752A2 (en) | 2022-02-23 |
| KR102605045B1 (en) | 2023-11-27 |
| EP3957752A3 (en) | 2022-06-15 |
| JP7557581B2 (en) | 2024-09-27 |
| AU2018252974A1 (en) | 2019-11-28 |
| US20230374145A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201804057TA (en) | An actuator housing for a metered dose inhaler device | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909457XA (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201907490XA (en) | Non-human animal models of retinoschisis | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201908226XA (en) | Rapamycin analog | |
| SG11201806424TA (en) | Therapeutic compounds |